Last updated: September 3, 2026
Plecanatide, marketed in the United States as Trulance by Bausch Health’s Salix Pharmaceuticals, is a guanylate cyclase-C agonist for chronic idiopathic constipation and irritable bowel syndrome with constipation. Its commercial trajectory has been shaped by a strong prescription market, competition from Linzess, limited global commercialization, and the transition from Synergy Pharmaceuticals to Bausch ownership.
Trulance generated approximately $300 million in annual U.S. net sales in the latest reported period, making it a mid-sized Salix asset rather than a portfolio anchor. The main commercial risk is generic entry through abbreviated new drug applications, or ANDAs. The main defense is a layered patent estate covering plecanatide, pharmaceutical compositions, and treatment methods.
What is plecanatide and how does Trulance work?
Plecanatide is a 16-amino-acid peptide that activates guanylate cyclase-C receptors on the luminal surface of intestinal epithelial cells. Activation increases cyclic guanosine monophosphate, which promotes chloride and bicarbonate secretion into the intestinal lumen. The resulting increase in intestinal fluid accelerates transit and softens stool.
Trulance is administered orally at 3 mg once daily. The drug has two FDA-approved adult indications:
| FDA indication |
Approval status |
| Chronic idiopathic constipation, or CIC |
Approved January 2017 |
| Irritable bowel syndrome with constipation, or IBS-C |
Approved January 2018 |
The product is a tablet with low systemic exposure. Its principal safety concern is diarrhea, including severe diarrhea that can cause dehydration. Trulance is contraindicated in patients younger than 6 years because of the risk of serious dehydration and is avoided in children ages 6 through 17 under the U.S. label.[1]
How large is the market for plecanatide?
The addressable market is the U.S. prescription market for CIC and IBS-C. Both conditions are large, chronic, and underdiagnosed, but commercial treatment is fragmented across branded drugs, generic laxatives, over-the-counter products, and prescription therapies.
Key branded competitors include:
| Product |
Active ingredient |
Manufacturer |
Primary positioning |
| Trulance |
Plecanatide |
Bausch Health / Salix |
CIC and IBS-C |
| Linzess |
Linaclotide |
AbbVie / Ironwood |
CIC and IBS-C |
| Amitiza |
Lubiprostone |
Takeda, previously Sucampo |
CIC and IBS-C |
| Motegrity |
Prucalopride |
Bausch Health / Salix |
CIC |
| Ibsrela |
Tenapanor |
Ardelyx |
IBS-C |
| MiraLAX and generic PEG |
Polyethylene glycol |
Multiple manufacturers |
OTC constipation treatment |
Linzess is the category leader by sales and prescription visibility. Trulance competes on similar clinical territory but has a smaller commercial footprint. Its once-daily dosing and low systemic absorption support physician adoption, while diarrhea rates, payer restrictions, and the availability of lower-cost alternatives constrain market expansion.
The market is relatively resistant to rapid substitution because treatment selection depends on symptom profile, insurance coverage, prior authorization, patient response, and tolerance. That supports recurring revenue but also creates pressure for manufacturer-funded copay programs and formulary discounts.
What are Trulance sales and the financial trajectory?
Trulance sales increased after Bausch acquired the product assets from Synergy Pharmaceuticals. The product benefited from Salix’s established gastroenterology sales infrastructure, payer relationships, and direct-to-consumer promotion.
Public company filings indicate the following approximate trajectory:
| Period |
Approximate Trulance net revenue |
Commercial development |
| 2017 |
Early launch period |
FDA launch for CIC |
| 2018 |
Growth period |
IBS-C indication added |
| 2019 |
Transition period |
Synergy assets acquired by Bausch |
| 2020-2021 |
Continued expansion |
Salix commercial platform scaled |
| 2022 |
More than $200 million |
Increased branded prescription penetration |
| 2023 |
Approximately $280 million |
Product established as a Salix growth asset |
| 2024 |
Approximately $300 million range |
Mature growth with generic-entry exposure |
The exact annual figure depends on whether the source reports gross product sales, net product sales, or segment-level revenue. Bausch reports Trulance within its Salix segment and separately identifies the product in its annual filings and earnings materials.[2]
The financial profile has several characteristics:
- Revenue is concentrated in the United States.
- Sales are recurring because patients use the product chronically.
- Gross margin is supported by the branded prescription model.
- Net pricing is reduced by rebates, discounts, chargebacks, and patient assistance.
- Future growth depends more on market share and payer access than on new indications.
Trulance is economically valuable to Bausch because it uses an existing commercial infrastructure. Incremental sales can be supported by the same gastroenterology sales organization that promotes Xifaxan, Motegrity, and other Salix products. The product is therefore strategically more important than its standalone revenue would suggest.
How does Trulance compare with Linzess and other constipation drugs?
Linzess is the closest branded comparator. Both drugs are guanylate cyclase-C agonists approved for CIC and IBS-C. The clinical distinction is not strong enough to eliminate direct substitution.
| Factor |
Trulance |
Linzess |
| Active ingredient |
Plecanatide |
Linaclotide |
| Drug class |
GC-C agonist |
GC-C agonist |
| CIC indication |
Yes |
Yes |
| IBS-C indication |
Yes |
Yes |
| Administration |
Once daily |
Once daily |
| Main adverse event |
Diarrhea |
Diarrhea |
| Commercial owner |
Bausch / Salix |
AbbVie / Ironwood |
| Market position |
Challenger |
Category leader |
| Generic risk |
ANDA litigation and patent risk |
Patent and settlement risk |
Motegrity provides a different mechanism through selective 5-HT4 receptor agonism and is used primarily for CIC. Amitiza competes in both indications but has a longer commercial history and different tolerability considerations. Ibsrela is positioned in IBS-C and can compete where patients have inadequate response or intolerance to GC-C agonists.
Generic polyethylene glycol remains a major economic competitor. Although its clinical use is less differentiated, its low cost makes it attractive to payers and patients. Branded products must demonstrate better symptom control, tolerability, convenience, or persistence to maintain premium pricing.
What patents protect plecanatide and Trulance?
Trulance has been protected by patents covering the plecanatide peptide, guanylate cyclase-C agonist compounds, pharmaceutical compositions, and methods of treating constipation-related disorders.
Public patent records and Orange Book listings identify the principal patent families associated with Trulance as including:
| Patent family or patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 7,041,786 |
Guanylate cyclase-C agonist compounds, including plecanatide-related matter |
Core composition protection |
| U.S. Patent No. 8,865,688 |
Plecanatide or related pharmaceutical compositions |
Product and formulation protection |
| U.S. Patent No. 9,018,311 |
Treatment methods involving GC-C agonists |
Method-of-use protection |
| Later continuation patents |
Formulation, dosing, and treatment claims |
Potentially later-expiring barriers |
The precise enforceability of each claim depends on the asserted claim language, prosecution history, terminal disclaimers, patent-term adjustment, and litigation outcome. A patent’s appearance in the Orange Book does not guarantee that every claim will survive an invalidity or noninfringement challenge.
The commercial significance of the estate is its layering. A generic applicant may need to defeat or design around more than the original composition patent. Formulation and method-of-use patents can delay launch even after a primary compound patent expires.
When does plecanatide lose exclusivity?
FDA regulatory exclusivity and patent exclusivity are separate.
| Exclusivity category |
Timing or status |
| New chemical entity exclusivity |
Five years from the January 2017 approval, subject to statutory exceptions |
| IBS-C supplemental exclusivity |
Supplemental approval did not recreate five-year NCE exclusivity |
| Orphan exclusivity |
None identified for Trulance |
| Pediatric exclusivity |
Must be confirmed from current FDA records |
| Patent exclusivity |
Depends on the expiration of listed and asserted patents |
| Biosimilar exclusivity |
Not applicable because plecanatide is regulated as a drug rather than a biologic |
The five-year NCE period protected Trulance from standard ANDA submission for the first four years, with a possible Paragraph IV submission during the fifth year. That regulatory barrier has expired.
The relevant commercial question is therefore patent-protected generic timing. Generic entry could occur after all enforceable Orange Book-listed barriers are expired, invalidated, or settled. A first-filer may also obtain 180-day generic exclusivity if statutory requirements are met.
Which companies are challenging Trulance patents?
Publicly reported ANDA litigation has involved generic applicants, including Lupin and Zydus-related entities. Bausch and affiliated parties have used Hatch-Waxman litigation to assert Trulance patents after Paragraph IV certifications.
A Paragraph IV certification states that an applicant believes a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The branded company generally has 45 days to file suit. A timely suit can trigger a statutory stay of FDA approval for up to 30 months, subject to court decisions and statutory exceptions.[3]
The central litigation issues typically include:
- Whether the proposed generic product practices composition claims.
- Whether the generic formulation infringes listed pharmaceutical-composition claims.
- Whether treatment claims are infringed by the generic label.
- Whether the asserted claims are obvious in view of earlier GC-C agonist research.
- Whether patent claims are adequately supported and enabled.
- Whether patent-term calculations and terminal disclaimers limit enforceability.
Settlement agreements can permit an earlier generic launch than the latest patent expiration date. The economic terms of such agreements may remain confidential. No reliable public conclusion should be drawn from the filing of litigation alone because the parties may settle, narrow claims, or obtain a judgment before FDA approval.
What is the FDA and Orange Book status of Trulance?
Trulance is FDA-approved as a prescription drug and is listed in the FDA Orange Book. Its approved dosage form is an oral tablet containing 3 mg plecanatide.
The Orange Book provides the regulatory reference point for:
- Approved strengths and dosage forms.
- Listed patents.
- Patent-use codes.
- Generic application certifications.
- Regulatory exclusivity periods.
Orange Book listing does not prevent a generic company from filing an ANDA. It requires the applicant to address each listed patent through a Paragraph I, II, III, or IV certification, or through a section viii statement for a method-of-use patent where permitted.
Plecanatide is a peptide drug, but it is not a biosimilar product. A competing product would normally proceed through the ANDA pathway if it can demonstrate pharmaceutical equivalence and bioequivalence. That makes the competitive pathway different from products requiring a 351(k) biosimilar application.
How strong is the plecanatide patent estate?
The estate is moderately strong commercially but weaker than a fully protected, late-life small-molecule franchise.
Strengths
- The product has a defined composition and mechanism.
- Trulance has multiple FDA-approved indications.
- The branded company can assert formulation and method-of-use patents.
- Chronic-use economics make even a limited period of generic delay valuable.
- Salix has experience defending gastrointestinal products in Hatch-Waxman litigation.
Weaknesses
- The core product was approved in 2017, so regulatory exclusivity has ended.
- GC-C agonist science predates plecanatide and creates prior-art exposure.
- Generic applicants can challenge composition, formulation, and method claims in parallel.
- Method-of-use claims may be vulnerable if generic labels omit or carve out the protected indication.
- The product is an oral peptide with a relatively straightforward dosage form.
The estate’s value depends on whether later patents claim commercially unavoidable aspects of the product. A patent that covers only a narrow formulation or a specific treatment population may delay some generic competition but not necessarily preserve the entire market.
What generic launch scenarios exist for Trulance?
Three scenarios are commercially relevant.
Launch after patent resolution
A generic applicant obtains approval after litigation establishes noninfringement or invalidity. This creates the highest probability of broad competition and rapid price erosion.
At-risk launch
A generic launches before final resolution after prevailing in district court or accepting litigation risk. The branded company can seek damages and an injunction. At-risk launch can produce rapid market share loss but exposes the generic to substantial damages.
Negotiated entry
The parties settle and agree to a launch date before the latest listed patent expiration. This is common where both sides face litigation uncertainty. The settlement may include a license, supply arrangement, or other commercial terms, subject to antitrust scrutiny.
For Trulance, a first generic launch would likely reduce net sales faster than prescription volume because payers can move utilization to the generic through formulary controls. Brand retention would depend on rebates, patient loyalty, physician preference, and the timing of generic substitution laws.
What manufacturing and intellectual-property barriers affect plecanatide?
Plecanatide manufacturing is more complex than conventional low-molecular-weight tablet production because the active ingredient is a synthetic peptide. Relevant barriers include:
- Peptide synthesis and purification.
- Control of sequence-related impurities.
- Oxidation and degradation control.
- Batch-to-batch potency and purity.
- Stability of the finished tablet.
- Bioequivalence of a low-systemic-exposure product.
- Control of tablet dissolution and local gastrointestinal delivery.
These barriers can increase development cost and delay generic approval, but they are not equivalent to the manufacturing barriers for a monoclonal antibody or other complex biologic. Several experienced generic manufacturers can produce synthetic peptides at commercial scale.
What licensing deals and ownership changes affect plecanatide?
Synergy Pharmaceuticals developed plecanatide and launched Trulance. Synergy later entered financial distress and filed for Chapter 11 bankruptcy protection. Bausch Health acquired substantially all of Synergy’s assets related to Trulance and other operations in 2019 for approximately $200 million, according to Bausch disclosures.[4]
The transaction changed Trulance from a standalone biotechnology commercialization story into a Salix portfolio asset. Bausch gained:
- The marketed Trulance product.
- Related intellectual property.
- Commercial rights and operating infrastructure.
- A product that could be integrated with an existing gastroenterology portfolio.
The acquisition also reduced standalone development risk because Bausch did not need to build a new sales organization from scratch. The trade-off was that Trulance became one product within a larger corporate portfolio, with capital allocation decisions influenced by Xifaxan, Motegrity, rifaximin lifecycle management, and Bausch’s leverage profile.
What revenue exposure does Bausch face from plecanatide?
Trulance is material to the Salix segment but not the principal driver of Bausch Health’s consolidated revenue. Xifaxan remains the dominant Salix product by sales. Trulance nevertheless has strategic value because it supplies recurring revenue in chronic gastrointestinal disease.
Generic entry could affect Bausch through:
- Lower net sales.
- Lower contribution margin.
- Reduced sales-force productivity.
- Higher rebates needed to retain commercial lives.
- Inventory and channel-management costs.
- Potential impairment of product-related intangible assets.
The impact would be concentrated in Salix rather than across the entire Bausch portfolio. A gradual generic launch would allow Bausch to preserve some branded volume, while multiple generic approvals could produce steep price erosion within several quarters.
How does plecanatide compare with other Bausch gastrointestinal assets?
| Asset |
Primary market |
Competitive position |
Main risk |
| Xifaxan |
Hepatic encephalopathy and IBS-D |
Salix anchor product |
Patent challenges and concentration |
| Trulance |
CIC and IBS-C |
Established branded challenger |
Generic entry and Linzess competition |
| Motegrity |
CIC |
Mechanistically differentiated |
Payer access and category competition |
| Relistor |
Opioid-induced constipation |
Specialty constipation product |
Generic and indication-specific competition |
Trulance offers broader constipation-market exposure than a narrow specialty product, but it lacks Xifaxan’s revenue scale and differentiation. Its value is best assessed as a durable cash-generating brand with a finite patent runway, not as a high-growth platform.
Key Takeaways
- Plecanatide is marketed as Trulance for CIC and IBS-C in adults.
- Bausch acquired the product and related assets from Synergy Pharmaceuticals in 2019.
- Annual Trulance sales reached approximately the $300 million range by the latest reported period.
- Linzess is the primary branded competitor; generic polyethylene glycol is the main low-cost substitute.
- FDA NCE exclusivity has expired, leaving patent protection as the principal barrier to ANDA approval.
- The patent estate includes composition, formulation, and method-of-use protections, but generic applicants have challenged the estate through Paragraph IV litigation.
- Plecanatide is a synthetic peptide drug, not a biologic, so biosimilar competition is not the applicable framework.
- Generic entry could materially reduce Trulance net sales because payer substitution is likely to accelerate price erosion.
- Trulance remains strategically useful to Bausch as part of the Salix gastrointestinal portfolio, but its financial contribution is smaller than Xifaxan’s.
FAQs
Is plecanatide the same drug as Trulance?
Yes. Plecanatide is the active ingredient in Trulance.
Is Trulance a biologic or a biosimilar?
No. Plecanatide is a synthetic peptide drug regulated through the conventional drug framework. Competitors would generally pursue an ANDA rather than a biosimilar application.
Does Trulance have patent protection outside the United States?
Patent coverage may exist in other jurisdictions, but commercial protection varies by country based on national filings, supplementary protection certificates, patent-term adjustments, and local litigation. U.S. protection is the primary commercial issue because Bausch’s marketed Trulance business is concentrated in the United States.
What is the largest commercial threat to Trulance?
Generic plecanatide is the largest direct threat. Linzess, OTC polyethylene glycol, payer restrictions, and patient switching are the main ongoing market pressures.
Can generic plecanatide launch before every Trulance patent expires?
Yes, if the generic applicant prevails in litigation, reaches a settlement permitting earlier entry, uses a valid section viii carve-out, or obtains approval after the relevant patent claims are held invalid, unenforceable, or not infringed.
References
- U.S. Food and Drug Administration. (2024). Trulance (plecanatide) prescribing information.
- Bausch Health Companies Inc. (2024). Annual report on Form 10-K for the year ended December 31, 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Bausch Health Companies Inc. (2019). Bausch Health acquires substantially all assets of Synergy Pharmaceuticals.
- U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for plecanatide-related patents.
